Budget impact of endovascular treatment for acute ischaemic stroke patients in the Netherlands for 2015-2021.

"Conflict of interest Erasmus Medical Centre received consulting fees from Stryker for A. van der Lugt. Maastricht University Medical Centre received consulting fees from Stryker and Cerenovus for W.H. van Zwam. C.B.L. Majoie received research grants from CVON/Dutch Heart Foundation, European Commission, Healthcare Evaluation Netherlands, TWIN Foundation and Stryker. C.B.L. Majoie and Y.B. Roos are shareholders of Nicolab, a company that focuses on the use of artificial intelligence for medical image analysis. D.W.J. Dippel and A. van der Lugt received grants from Stryker, Penumbra Inc., Medtronic, Cerenovus, Dutch Heart Foundation, Brain Foundation Netherlands, Netherlands Organisation for Health Research and Development and Thrombolytic Science, all unrestricted and paid to Erasmus Medical Centre. L.A. van den Berg, O.A. Berkhemer, P.S.S. Fransen, D. Beumer, R.J. van Oostenbrugge and M.G.W. Dijkgraaf declare that they have no competing interests."

"Funding This work was supported by the Netherlands Organisation for Health Research and Development (ZonMw) and is registered in the Dutch Trial Register (number 5073). The MR CLEAN study was funded by the Dutch Heart Foundation (Hartstichting) and through unrestricted grants from AngioCare BV, Covidien/EV3, MEDAC GmbH/LAMEPRO, Stryker and Penumbra Inc. The MR CLEAN trial is registered in the Dutch Trial Register (number 1804) and in the ISRCTN registry (number ISRCTN10888758). The MR CLEAN Registry is funded by unrestricted grants from Toegepast Wetenschappelijk Instituut voor Neuromodulatie, Twente University (TWIN), Erasmus Medical Centre, Amsterdam University Medical Centres and Maastricht University Medical Centre. The study sponsors were not involved in the study design, study conduct, protocol review or manuscript preparation or review."

"FundingThis work was supported by the Netherlands Organisation for Health Research and Development (ZonMw) and is registered in the Dutch Trial Register (number 5073). The MR CLEAN study was funded by the Dutch Heart Foundation (Hartstichting) and through unrestricted grants from AngioCare BV, Covidien/EV3, MEDAC GmbH/LAMEPRO, Stryker and Penumbra Inc. The MR CLEAN trial is registered in the Dutch Trial Register (number 1804) and in the ISRCTN registry (number ISRCTN10888758). The MR CLEAN Registry is funded by unrestricted grants from Toegepast Wetenschappelijk Instituut voor Neuromodulatie, Twente University (TWIN), Erasmus Medical Centre, Amsterdam University Medical Centres and Maastricht University Medical Centre. The study sponsors were not involved in the study design, study conduct, protocol review or manuscript preparation or review."